← Back to Search

[14C]-LY3871801 for Healthy Subjects

Phase 1

Waitlist Available

Research Sponsored by Eli Lilly and Company

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up predose up to day 7 post dose

Awards & highlights

Study Summary

This trial studies how much of a study drug is absorbed, broken down, and removed from the body in healthy male adults. It lasts up to 9 weeks.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ predose up to day 7 post dose

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~predose up to day 7 post dose

This trial's timeline: 3 weeks for screening, Varies for treatment, and predose up to day 7 post dose for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Fecal Excretion of LY3871801 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered

Urinary Excretion of LY3871801 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered

Secondary outcome measures

PK: AUC [0-∞] of Total Radioactivity in Plasma and Whole Blood

PK: Cmax of Total Radioactivity

PK: Maximum Concentration (Cmax) of [¹⁴C]-LY3871801

+3 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: [14C]-LY3871801Experimental Treatment1 Intervention

Single dose of [¹⁴C]-LY3871801 administered orally

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

[14C]-LY3871801

2023

Completed Phase 1

~10

Do I qualify?Apply below to find out

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor

2,617 Previous Clinical Trials

3,201,192 Total Patients Enrolled

Study DirectorEli Lilly and Company

1,346 Previous Clinical Trials

405,386 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the minimum age requirement for this trial above or below 20 years old?

"The age range for eligible participants in this medical trial is between the ages of 18 and 65."

Answered by AI

Are there any available opportunities for participants in this experiment?

"The information supplied on clinicaltrials.gov shows that the recruitment for this study has ceased, as it was initially posted and last updated on September 15th 2023. Nonetheless, there are 834 other medical trials currently searching for test subjects."

Answered by AI

What level of hazard does [14C]-LY3871801 pose to individuals?

"The safety of [14C]-LY3871801 is provisionally rated 1, as it has only been tested in the early stages of a clinical trial, and thus does not have substantial evidence to support its effectiveness or safety."

Answered by AI

Do I fulfill the qualifications to participate in this medical experiment?

"To have a chance at being selected for this study, individuals must be between the ages of 18 and 65 with no pre-existing medical conditions. The research team is searching for around 8 volunteers to participate."

Answered by AI

What is the ultimate ambition of this investigation?

"This trial aims to measure the Fecal Excretion of LY3871801 Radioactivity within a seven-day period post-dosage. Secondary objectives are related to pharmacokinetics such as measuring AUC [0-∞] and Cmax of both [¹⁴C]-LY3871801 and Total Radioactivity."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Study of Carbon-14-Labelled [14C] LY3871801 in Healthy Male Participants

2023. "A Study of Carbon-14-Labelled [14C] LY3871801 in Healthy Male Participants". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06049108.